Gannex is a subsidiary of Hong Kong-listed Ascletis Pharma (HKEX:1672), a Shanghai-headquartered company focused on viral diseases, oncology and NASH. It has two clinical stage NASH drug candidates with global rights against two different targets (THRβ and FXR) and one clinical-stage PBC drug candidate.